PHASE II, EXPLORATORY, MULTICENTER, NON RANDOMIZED, SINGLE AGENT COHORT STUDY TO DETERMINE BEST TUMOR RESPONSE WITH TRASTUZUMAB EMTANSINE IN HER2 OVEREXPRESSING SOLID TUMORS
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Bladder cancer; Cholangiocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms KAMELEON
- Sponsors Roche
- 30 Nov 2017 Planned End Date changed from 20 Dec 2019 to 31 Mar 2018.
- 30 Nov 2017 Planned primary completion date changed from 20 Dec 2019 to 31 Mar 2018.
- 27 Nov 2017 This trial has been discontinued in Spain.